SCHEMBL95685

SCHEMBL95685

CCOC(=O)/C(=N\O)c1csc(N)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 0.62
KMT2A Q03164 9/20 0.62
MAPT P10636 8/20 0.62
ALDH1A1 P00352 4/20 0.62
NPC1 O15118 1/20 0.62
RAB9A P51151 1/20 0.62
TDP1 Q9NUW8 3/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
LMNA P02545 2/20 0.54
MAPK1 P28482 2/20 0.54
GAA P10253 3/20 0.46
NPSR1 Q6W5P4 3/20 0.46
RECQL P46063 1/20 0.46
TSHR P16473 2/20 0.43
HTT P42858 3/20 0.41
KDM4E B2RXH2 1/20 0.41
PKM P14618 1/20 0.41
HPGD P15428 2/20 0.41
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9659527 1.00 MEN1 (0.62) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL95686 1.00 MEN1 (0.62) MEN1KMT2AMAPTALDH1A1NPC1
Hydrochloric Acid SCHEMBL9076121 0.99 MEN1 (0.65) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL10538827 0.86 MAPT (0.63) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL1143128 0.86 MAPT (0.59) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL8645013 0.86 MAPT (0.63) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL8645016 0.86 MAPT (0.63) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL1143127 0.86 MAPT (0.59) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL9076641 0.86 MAPT (0.59) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL4837027 0.85 MEN1 (0.47) MEN1KMT2AMAPTALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0555769-B1 Process for the preparation of Cephem-Prodrug-esters HOECHST AG (DE) 1999-09-15 EP claimed
US-4988816-A Chemical intermediates for cephalosporin antibiotics ROUSSEL UCLAF (FR) 1991-01-29 US claimed
JP-7173140-A None JP disclosed
JP-7082253-A None JP disclosed
JP-7179445-A None JP disclosed
WO-2026107208-A1 COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS THE METHODIST HOSPITAL (US) 2026-05-21 WO disclosed
US-20230227444-A1 BETA-LACTAM COMPOUND, USE THEREOF AND PREPARATION METHOD THEREFOR INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2023-07-20 US disclosed
US-20230227444-A1 BETA-LACTAM COMPOUND, USE THEREOF AND PREPARATION METHOD THEREFOR INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2023-07-20 US disclosed
US-20230114728-A1 PENICILLIN-BINDING PROTEIN INHIBITORS VenatoRx Pharmaceuticals, Inc. 2023-04-13 US disclosed
US-11332485-B2 Penicillin-binding protein inhibitors VenatoRx Pharmaceuticals, Inc. (US) 2022-05-17 US disclosed
US-11332485-B2 Penicillin-binding protein inhibitors VenatoRx Pharmaceuticals, Inc. (US) 2022-05-17 US disclosed
US-4487937-A CEPHALOSPORIN INTERMETIATE ROUSSEL UCLAF (FR) 1984-12-11 US disclosed
US-4483981-A ANTIBIOTICS, BACTERICIDES ROUSSEL UCLAF (FR) 1984-11-20 US disclosed
US-4386210-A CEPHALOSPORIN ANTIBIOTICS ROUSSEL UCLAF (FR) 1983-05-31 US disclosed
US-4376203-A ANTIBIOTIC ROUSSELL UCLAF (FR) 1983-03-08 US disclosed
US-4288434-A Cephalosporanic acid derivatives ROUSSEL UCLAF (FR) 1981-09-08 US disclosed
US-4283396-A 3-Acetoxymethyl-7-(hydroxyiminoacetamido)-cephalosporanic acid derivatives ROUSSEL UCLAF (FR) 1981-08-11 US disclosed
US-4278671-A ANTIBIOTICS, BACTERICIDES TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1981-07-14 US disclosed
US-4196205-A ANTIBIOTICS, BACTERICIDES ROUSSEL UCLAF (FR) 1980-04-01 US disclosed
US-4152432-A ANTIBIOTICS ROUSSEL UCLAF (FR) 1979-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227444-A1 BETA-LACTAM COMPOUND, USE THEREOF AND PREPARATION METHOD THEREFOR COASY, CYP51A1, DCXR MEN1 1182/4885KMT2A 4259/4885MAPT 4462/4885
US-20230114728-A1 PENICILLIN-BINDING PROTEIN INHIBITORS PEPD, BPGM, EBPL MEN1 3629/4885KMT2A 2536/4885MAPT 3146/4885
US-11332485-B2 Penicillin-binding protein inhibitors PEPD, BPGM, EBPL MEN1 3629/4885KMT2A 2536/4885MAPT 3146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.